Abstract YO40
Case summary
Introduction: Giant cell tumor (GCT) of bone are benign but locally aggressive primary bone tumors.They occur predominantly in long bones of adolescents and young adults typically in the epiphysis. Malignant giant cell tumors of bone (MGCTB) are rare, occurring in less than 1% of GCT of bone. Primary malignant GCT (PMGCT) is a high-grade sarcoma that arises side by side with benign GCTs. Secondary malignant GCT (SMGCT) is a high-grade sarcoma that occurs at the site where a GCTwas previously treated either by radiotherapy (radiation-induced form) or surgery (evolutionary form).
Case Description: A 30 year old female presented with progressive swelling and pain around the left knee for six months without any significant preceding history. X- Ray showed an expansile lytic lesion involving epiphysis of tibia and features suggestive of GCT. She underwent tumor resection and custom made prosthesis replacement. Post op histopathology showedGCT.Six months later the pain and swelling recurred. She was re evaluated with CT left leg which showed recurrent GCT 20x20 cm with soft tissue extension.Biopsy showed malignancy with GCT.Whole body FDG-PET CT was suggestive of tumor recurrence in left proximal tibia with associated soft tissue mass with inguinal nodal and pulmonary metastasis. She received palliative RT 30Gy in 10 fractions.Due to local progression she underwent palliative above knee amputation. Post op histopathology was suggestive of giant cell rich sarcoma.She received 3 cycles of chemotherapy with cisplatin and adriamycin. She expired after 3rd cycle of chemotherapy.
Discussion:PMGCT typically is difficult to distinguish from giant cell tumor of bone, as clinical and radiographic presentation of PMGCT can mimic that of a benign lesion. Malignancies in GCTs are extremely rare events. Since these are aggressive tumors with poor prognosis, it is important that they be recognized at an early stage so that they can be treated adequately by aggressive surgery and chemotherapy.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract